flinch strong
stryker corp ticker put clean strong organ revenu
growth adjust sell day comp adjust growth
last two quarter ep growth margin expans
rais guidanc slightli rel expect syk line street
high expect head quarter see noth number
caus concern confid syk abil continu similar growth
trajectori high clear top bottom line driver
like remain one reliabl doubl digit ep growth compound
healthcar rais po new po base
ep vs ep prior reiter buy rate
syk comment spine slightli expect low singl digit
growth vs mid-singl digit expect deal integr new product scale
expect drag long clean mako number
strong unit place almost y/i growth procedur
placement went competit account purchas
backlog strong increas demand outsid us hip knee
deliv comp sell day adjust acceler hip knee
capit purchas trend remain strong syk neurovascular growth
strong improv view syk encourag
lesser degre
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
medic technolog compani
oper two busi segment orthoped
implant busi produc implant use joint
replac trauma spine craniomaxillofaci
surgic equip orthoped
hardwar well patient handl emerg
buy rate given top-tier
diversifi organ revenu growth outlook
balanc sheet capac believ one
best manag compani med-tech
tabl constant currenc hip growth adjust sell day
tabl average constant currenc hip growth adjust sell day
tabl constant currenc knee growth adjust sell day
tabl average constant currenc knee growth adjust sell day
po deriv ep estim premium
larg cap med-tech group believ justifi given lead organ growth
success track record also see point ep upsid potenti
well
upsid risk price object announc activ better
expect growth mako greater-than-expect impact share
loss consist strong earn growth given increasingli diversifi
downsid risk price object becom less confid execut
 econom impact surg busi lower capital-expenditure spend
wors anticip mako take market share expect
bob hopkin herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
becton dickinson compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
